COPD in the Time of COVID-19

Cross-Sectional Observation Telephone Survey Study to Understand the Changes in COPD Exacerbation Patterns and Potential Causes of These During the COVID-19 Pandemic

This cross-sectional observational study will collect information about changes in exacerbation frequency and behaviour amongst a clinical cohort of severe or complex COPD clinic patients. This will be done through a combination of telephone survey and access to electronic heath records.

Study Overview

• Status: Unknown
• Conditions: COPD; COPD Exacerbation

Detailed Description

This study will be a cross-sectional observational study utilising a telephone survey.

After obtaining informed verbal consent participants will be asked to recall their symptoms, exacerbation events and exacerbation medication usage over the periods of 01/03/20 - 14/03/20 (pre-lockdown) and then 15/03/20 to 30/04/20 (lockdown).

A structured survey will follow on from this asking questions regarding behaviour including self-isolation, shielding, other household contacts, visitors to the home, arrangements for shopping, changes in smoking behaviour (including that of other smokers in the household), medication changes, self-reported change in use of preventer medication, self-reported change in walking/activity levels and self-reported changes in anxiety levels.

Baseline clinical data will subsequently also be collected from the comprehensive respiratory review previously performed in the complex COPD clinic (comprising both hospital and GP records.) This will include previous AECOPD phenotyping (eosinophil levels, sputum culture and viral PCR), previous lung function testing, prescribed medication, BMI and smoking status and history. Previous AECOPD events will be counted and graded based on GP antibiotic or steroid prescriptions and hospital admissions.

Participants will be contacted once as part of the main study following verbal informed consent (via telephone). This will be a brief survey as described above, lasting approximately 20 minutes. A second similar survey will take place up to 12 months after the initial contact to evaluate longitudinal changes associated with the lockdown (further details on this will be submitted as an amendment at a later date due the shifting and unpredictable nature of the COVID-19 pandemic and lockdown, this will be prior to initiating these second calls).

Additional clinical data will be collected from healthcare records to quantify disease severity. Participant postcodes will be collected to link results with changes in local air pollution as recorded or estimated during the COVID-19 lockdown.

• Study Type: Observational
• Enrollment (Actual): 160

Contacts and Locations

Study Locations

• United Kingdom
  • Leicester, United Kingdom, LE3 9QG
    • NIHR Leicester Biomedical Research Centre (Respiratory), Glenfield Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients known to have COPD and previously seen in the Complex COPD Clinic at the Glenfield Hospital, Leicester.

Description

Inclusion Criteria:

1. Confirmed clinical diagnosis of COPD
2. Ability to provide informed verbal consent via English language telephone consultation
3. Adults aged over 40 years

Exclusion Criteria:

1. Patients currently admitted to hospital
2. Unwilling/unable to provide informed consent

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Glenfield Complex COPD Clinic Cohort; Patients previously seen in the complex COPD clinic at the Glenfield Hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in COPD Exacerbation Rate	The primary outcome will be the change in number of moderate or severe AECOPD events over the 46 days from the 15th March, 2020 to 30th April, 2020 compared to the same 46 day period in 2019.	46 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in number of Severe AECOPD events during period of interest in 2020 from same period in 2019.	46 days
Change in Moderate AECOPD events during period of interest in 2020 from same period in 2019.	46 days
Social contact changes during i) pre-lockdown and ii) lockdown period	46 days
Household contacts during i) pre-lockdown and ii) lockdown period	46 days
Household visitors during i) pre-lockdown and ii) lockdown period	46 days
Regular shopping behaviour during i) pre-lockdown and ii) lockdown period	46 days
Medication changes during i) pre-lockdown and ii) lockdown period	46 days
Reported change in regular medication usage during i) pre-lockdown and ii) lockdown period	46 days
Change in physical activity levels during i) pre-lockdown and ii) lockdown period	46 days
Change in anxiety levels during i) pre-lockdown and ii) lockdown period	46 days
Perceived fear of hospitalisation during COVID-19 period	46 days
Patient reported changes in perception of symptoms, need for hospitalisation and availability and safety of healthcare resources thought semi-structured interviews in 20 patients (nested qualitative study)	46 days
Association between changes in AECOPD event rate and changes in local air pollution during the COVID-19 lockdown	46 days

Collaborators and Investigators

• Sponsor: University of Leicester
• Collaborators: University Hospitals, Leicester
• Investigators: Principal Investigator: Neil J Greening, PhD, University of Leicester

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2020
• Primary Completion (Actual): June 8, 2020
• Study Completion (Anticipated): June 1, 2021

Study Registration Dates

• First Submitted: May 27, 2020
• First Submitted That Met QC Criteria: May 27, 2020
• First Posted (Actual): May 29, 2020

Study Record Updates

• Last Update Posted (Actual): November 3, 2020
• Last Update Submitted That Met QC Criteria: November 2, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Keywords: COPD; COVID-19; AECOPD
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 0778

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No